LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Search

Revvity Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

94.12 2.02

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

92.3

Max

94.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-8.6M

47M

Pardavimai

-21M

699M

P/E

Sektoriaus vid.

46.938

106.172

Pelnas, tenkantis vienai akcijai

1.18

Dividendų pajamingumas

0.3

Pelno marža

6.675

Darbuotojai

11,000

EBITDA

-14M

181M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.43% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.30%

2.31%

Kita Ex Dividend data

2026-01-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-708M

11B

Ankstesnė atidarymo kaina

92.1

Ankstesnė uždarymo kaina

94.12

Naujienos nuotaikos

By Acuity

23%

77%

37 / 374 reitingas Healthcare

Revvity Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-20 23:07; UTC

Rinkos pokalbiai

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

2025-11-20 22:22; UTC

Rinkos pokalbiai

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

2025-11-20 22:08; UTC

Rinkos pokalbiai

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

2025-11-20 21:57; UTC

Uždarbis

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

2025-11-20 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-11-20 21:31; UTC

Uždarbis

Nvidia's Strong Results Show AI Fears Are Premature -- Update

2025-11-20 21:23; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

2025-11-20 21:07; UTC

Uždarbis

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025-11-20 21:06; UTC

Uždarbis

Webull 3Q Rev $156.9M >BULL

2025-11-20 21:06; UTC

Uždarbis

Webull 3Q EPS 7c >BULL

2025-11-20 21:05; UTC

Uždarbis

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

2025-11-20 21:04; UTC

Uždarbis

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

2025-11-20 21:04; UTC

Uždarbis

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

2025-11-20 21:04; UTC

Uždarbis

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Rev $21B-$21.19B >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit 1Q Consumer Rev $894M

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Guidance

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit 1Q Global Business Solutions Rev $3B

Akcijų palyginimas

Kainos pokytis

Revvity Inc Prognozė

Kainos tikslas

By TipRanks

20.43% į viršų

12 mėnesių prognozė

Vidutinis 111.1 USD  20.43%

Aukščiausias 125 USD

Žemiausias 100 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Revvity Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

8

Pirkti

3

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

37 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat